Trial Profile
An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs APZ 2 (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors RHEACELL
- 06 Oct 2022 Status changed from active, no longer recruiting to completed.
- 09 Jun 2022 This trial has been completed in France, according to European Clinical Trials Database record.
- 31 Mar 2020 This trial has been suspended in Austria as per European Clinical Trials Database record.